Milvexian Fails to Cut Heart Events After Acute Coronary Syndrome in Major Trial
The phase III LIBREXIA ACS trial found the factor XIa inhibitor milvexian offered no benefit over placebo in preventing recurrent cardiovascular events.
Summary
A large phase III clinical trial called LIBREXIA ACS tested milvexian, a drug that blocks a clotting protein called factor XIa, in patients who recently had a heart attack or unstable angina. The trial, stopped early for futility, found milvexian did not reduce the risk of cardiovascular death, heart attack, or stroke compared to placebo when added to standard antiplatelet therapy. Roughly 5.4% of milvexian patients and 5.1% of placebo patients experienced one of these events over about 12 months. The one encouraging finding was that milvexian did not raise the risk of serious bleeding. Two related trials — in atrial fibrillation and stroke prevention — are still ongoing, meaning the story of this drug class is not yet finished.
Detailed Summary
Factor XIa inhibitors represent a promising new class of anticoagulants designed to reduce dangerous blood clots with a potentially lower bleeding risk than existing blood thinners. The hope was that blocking this clotting pathway could offer heart patients an extra layer of protection after a serious cardiac event without the bleeding complications that limit current drugs.
The LIBREXIA ACS trial enrolled thousands of high-risk patients who had recently experienced an acute coronary syndrome — a category including heart attacks and unstable angina. Patients received either milvexian or placebo on top of standard antiplatelet therapy. After a median follow-up of about 12 months, 5.4% of the milvexian group and 5.1% of the placebo group suffered a major cardiovascular event, a statistically insignificant difference with a hazard ratio of 1.05. The trial was halted early when an interim analysis showed it was unlikely to meet its primary goal.
The clearest positive signal was on safety. Severe bleeding events occurred in just 0.3% of patients in both groups, suggesting milvexian does not increase bleeding risk — an important reassurance given that two other large trials of the drug, in atrial fibrillation and stroke prevention, are still running.
Experts note that the near-universal use of revascularization procedures (92% of patients) and prolonged dual antiplatelet therapy in this study may have left little room for milvexian to add benefit. Despite being stopped early, the confidence intervals were narrow enough that a meaningful treatment effect is unlikely to have been missed.
For health-conscious adults and clinicians, the takeaway is that factor XIa inhibition does not yet have a proven role after acute coronary syndrome, but its favorable safety profile keeps it viable for other cardiovascular indications. Ongoing trials will clarify whether this mechanism can deliver real-world benefit in different patient populations.
Key Findings
- Milvexian did not reduce cardiovascular death, heart attack, or stroke vs placebo (HR 1.05, P=0.50) over ~12 months.
- Severe bleeding rates were identical at 0.3% in both groups, confirming a favorable safety profile.
- The trial was stopped early for futility after an interim analysis; narrow CIs rule out a missed meaningful benefit.
- High revascularization rates (92%) and dual antiplatelet use may have limited the drug's ability to show added benefit.
- Two ongoing phase III trials (LIBREXIA AF and LIBREXIA STROKE) continue, with topline data expected soon.
Methodology
This is a meeting-coverage news report from MedPage Today summarizing phase III randomized controlled trial results (LIBREXIA ACS) presented at the ESC Congress 2026 and simultaneously published in the New England Journal of Medicine. The evidence basis is high-quality: a large, placebo-controlled, blinded RCT with a time-to-event primary endpoint and independent DSMB oversight.
Study Limitations
The trial was stopped early, limiting total event counts, though confidence intervals were narrow enough to be informative. High background therapy (revascularization and dual antiplatelet) in this specific population may not generalize to settings with lower baseline treatment intensity. The article is a news summary; readers should consult the full NEJM publication for complete methodology and subgroup data.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: